Abstracts tagged "gout and morbidity and mortality"

Abstract Number: 1130 • 2017 ACR/ARHP Annual Meeting
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Sarah Keller¹, Sharan K. Rai², Na Lu¹, April Jorge³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Alcohol is a well-established risk factor for gout. However, more than 60 prospective studies have also shown that moderate alcohol intake is associated with…
Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Geraldo Castelar-Pinheiro¹ and Aleksandra Turkiewicz³, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
Abstract Number: 3125 • 2016 ACR/ARHP Annual Meeting
Secular Trend of Premature Mortality in Gout: A Contrast from Rheumatoid Arthritis
Sharan K. Rai^1,2, Leo Lu³, Yuqing Zhang⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Gout and rheumatoid arthritis (RA), the two most common inflammatory arthritides, are both associated with premature mortality. General population-based studies have found substantially reduced…
Abstract Number: 179 • 2014 ACR/ARHP Annual Meeting
Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis
Chang-Fu Kuo^1,2, Matthew J. Grainge³, Christian Mallen⁴, Weiya Zhang¹ and Michael Doherty⁵, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ⁴Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose Although current guidelines recommend allopurinol as a first-line urate-lowering treatment for gout patients, whether the balance of potential benefits and risks can translate to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].